SMi are proud to introduce their fourth annual Biosimilars & Biobetters conference due to met on the 1 & 2 October 2013 in London. This conference aims to build on the progress made in the previous extremely successful meetings; further developing the ideas and strategies that have been made over the past twelve months.
Biological therapeutics promises to be a radical step forward for many pharmaceutical companies pipelines; patent expiry dates are playing an important role in why many pharma companies are pushing for innovative steps to be taken in this field. Following on from our huge 2012 event, we aim to bring together pharma, biotech, CROs with regulatory bodies and legal experts to explain the advantages and disadvantages of a hugely lucrative but young market.
There will be case studies from those who are both developing and distributing follow on biologics. With analysis of key trends in biologic pipelines, methods in clinical trials for biosimilar approval, a review of emerging markets, assessment of biosimilar manufacturing, post approval strategy and future forecasting for follow on biologics.
There will be case studies from those who are both developing and distributing follow on biologics. With analysis of key trends in biologic pipelines, methods in clinical trials for biosimilar approval, a review of emerging markets, assessment of biosimilar manufacturing, post approval strategy and future forecasting for follow on biologics.
- Discover guidelines issues by regulatory bodies such as the FDA & EMEA and how they impact your business model
- Understand market access pathways and see case studies on successful products
- Hear from the development process from pre-clinical focus from pharma doing the research
- Learn from expert legal opinions on intellectual property and patent protection programmes
- Evaluate global research co-operation producing blockbuster Biosimilars
- Develop clinical plan for biosimilar and biobetter drug design for your clinical trial - When is the right time to proceed
- Intellectual Property
- Legislation and Policy Advice
- Business Development
- Licensing
- Manufacturing
- APIs
- Bioequivalence
- Drug and Safety Assessment
- Market Strategy
- Regulatory Affairs
Ablynx; Armengaud-Guerlain; Arnold and Porter; AstraZeneca; Atheln Biomed; BRG; Bristows; Brockmeyer Biopharma GmbH; Business Insights; Crown CRO; Edenbiodesign Ltd; Eli Lilly; Flamel Technologies; Fresenius Kabi Deutschland GmbH; Frontline Pharma Consulting Ltd; Genentech; GenericsWeb; GlaxoSmithKline; Glycotope GmbH; Harvest Moon Pharmaceuticals; I B R Inc Institute For Biopharmaceutical Research; IDDI; IMS Health; Interpharm Consultancy; JustPharmaReports; Medical Industry Week; Medimmune; Menarini; Merck; Pinsent Masons; PolyTherics Ltd.; Roche; Ropes & Gray; Sanofi-Aventis; Takeda Pharmaceuticals; Technology Networks; TRISKEL Integrated Services S.A; UCB;